Researchers at the HUN-REN Research Centre for Natural Sciences (HUN-REN TTK) have developed a new method for detecting neutralising antibodies (Nabs), offering the potential for safer and more successful AAV gene therapies. 

The novel ‘Constant Serum Concentration’ (CSC) assay, published in the journal Nature Gene Therapy, correctly identified up to 21.7% more patients with potentially therapy-blocking antibodies than conventional methods, addressing a critical blind spot in preclinical screening. 

Adeno-associated virus (AAV) gene therapies represent a revolutionary approach for treating genetic diseases, but their effectiveness can be blocked by pre-existing antibodies in a patient’s blood. Standard assays used to screen patients work by diluting a patient’s serum, but this process also dilutes other components in the blood, creating an unstable baseline that can mask the presence of low but clinically important levels of neutralising antibodies. This means some patients deemed ‘eligible’ for a multi-million-dollar therapy might harbour antibodies that could cause it to fail or be less effective. 

The new CSC assay, developed by the Momentum Visual Systems Neuroscience lab, solves this problem by maintaining a constant level of total serum in every test sample. The crucial change stabilises the testing environment, removing the background noise that plagued older methods. The result is a much clearer and more sensitive signal. 

“It’s the difference between trying to spot a tiny ripple in a choppy lake versus on a perfectly still pond,” explains Dániel Hillier of HUN-REN TTK, a lead author on the study. “We recognised a fundamental vulnerability in how the field was measuring these antibodies. Even low levels can have a profound impact on whether a life-changing therapy works. We needed a more reliable tool to ensure we are giving patients the best possible chance of success.” 

HUN-REN TTK research publicly available

Results from the study demonstrated a dramatic improvement in accuracy. When testing human serum samples provided by the Department of Ophthalmology at Semmelweis University, the CSC assay reclassified up to 21.7% of samples that a conventional assay had incorrectly labelled as ‘negative’ for neutralising antibodies. In preclinical models designed to mimic long-term immunity, the CSC method was also able to detect these antibodies for a full year longer than the standard assay.  

“This isn’t just an incremental improvement; it provides a more accurate framework for interpreting seropositivity,” said Beatrix Kovács, the paper’s first author and Researcher at HUN-REN TTK. “With the CSC assay, we can make more informed decisions about patient selection and redosing strategies, which has direct translational relevance for clinical trials currently underway.” 

Researchers from HUN-REN TTK have made the protocol for the CSC assay publicly available, aiming to accelerate adoption and standardisation of the approach across the industry. 

 

Bruno Quinney, Content Teams, DDW